繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

UPDATE 1-MultiPlan merges with Churchill Capital to go public in $11 bln deal

2020-07-13 09:12

(Adds details from statement, background)
   July 12 (Reuters) - Churchill Capital Corp III , a special purpose acquisition company (SPAC), and MultiPlan Inc said they have reached a definitive agreement to merge in a deal worth about $11 billion that will take the U.S. healthcare services firm public.
   The deal represents the largest-ever SPAC merger, said Multiplan parent Hellman & Friedman (H&F).
   The merged company will operate under the name MultiPlan, which will be listed on NYSE, the companies said in a joint statement on Sunday, adding that the deal will expand MultiPlan's data analytics platform.
   MultiPlan will receive up to $3.7 billion of new equity or equity-linked capital that will reduce the firm's debt.
   The transaction includes $1.3 billion worth of fully committed common stock at $10 a share and $1.3 billion in convertible debt, convertible at $13 per share.
   MultiPlan Chief Executive Mark Tabak will be CEO of the combined company, with David Redmond staying on as chief financial officer.
   As a public company, MultiPlan will be better equipped to expand organically with adjacent mergers and investments in new technology, Tabak said.
   Under the deal, Churchill, which went public in February, will provide up to $1.1 billion of cash raised during its initial public offering (IPO).
   The deal comes a month after Reuters reported that billionaire investor William Ackman's hedge fund Pershing Square Capital Management has filed confidentially with U.S. regulators for an IPO of a blank-check investment vehicle that could raise over $1 billion.
   H&F, which acquired MultiPlan in 2016, will be the merged entity's largest shareholder.
   The parties expect the transaction to be completed by the end of October 2020.

(Reporting by Maria Ponnezhath in Bengaluru; Editing by
Muralikumar Anantharaman and Christopher Cushing)
((Maria.Ponnezhath@thomsonreuters.com; +91 8061822749;)

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。